| For: | Yin X, Deng N, Ding XY, Chen JL, Sun W. CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma. World J Gastroenterol 2025; 31(7): 101672 [PMID: 39991685 DOI: 10.3748/wjg.v31.i7.101672] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i7/101672.htm |
| Number | Citing Articles |
| 1 |
Caifeng Gong, Jinglong Huang, Dandan Cao, Tianyi Liu, Qi Cai, Shuhui You, Yongkun Sun, Zhichao Jiang, Wei Wang, Lin Yang, Hong Zhao, Wen Zhang, Aiping Zhou. Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs. Therapeutic Advances in Medical Oncology 2025; 17 doi: 10.1177/17588359251407052
|
| 2 |
Xiaoxia Wang, Shuo Wang, Jun Lu, Songtao Liu. Lenvatinib Versus Bevacizumab in Combination With Anti‐PD‐1/PD‐L1 Therapy for uHCC: A Meta‐Analysis of East Asian Studies. Liver International 2026; 46(5) doi: 10.1111/liv.70647
|
| 3 |
Shou-Wu Lee, Yi-Jie Huang, Ying-Cheng Lin, Hsin-Ju Tsai, Chia-Chang Chen, Chung-Hsin Chang, Teng-Yu Lee, Yen-Chun Peng. CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy. Cancers 2025; 17(18) doi: 10.3390/cancers17183058
|
| 4 |
Lilong Zhang, Yuefeng Zhang, Kunpeng Wang, Jiarui Feng, Chen Chen, Xinfei Liu, Weixing Wang. Prognostic impact of CRAFITY score in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. iScience 2025; 28(12) doi: 10.1016/j.isci.2025.113976
|